The neurotechnology
industry, all in one place.
213+ companies, funding rounds, clinical trials, and breakthroughs — tracked daily for founders, investors, and researchers.
213+
Companies tracked
across 9 categories
$18B+
Funding tracked
in VC investment
24+
News published
industry articles
Every Sunday
Weekly digest
NeuroTech Digest
Browse by category
View all 213 companies →Featured companies
COMPASS Pathways
Psychedelics
COMPASS Pathways is a mental health care company focused on accelerating patient access to psilocybin therapy, with their proprietary COMP360 psilocybin formulation in Phase 3 trials for treatment-resistant depression. They are one of the most advanced and well-funded psychedelic medicine companies globally.
Kernel
Research Tools
Kernel builds non-invasive neuroimaging helmets — the Flow (TD-fNIRS) and Flux (MEG) systems — designed to make high-resolution brain scanning accessible outside of hospital settings. Founded by Bryan Johnson, the company aims to democratize neuroscience research and brain measurement at scale.
MindMed
Psychedelics
MindMed is a clinical-stage psychedelic medicine company developing novel therapeutics derived from LSD, MDMA, and ibogaine analogs for neurological and psychiatric disorders. Their lead asset MM120 (LSD tartrate) has shown promising Phase 2b results for generalized anxiety disorder.
Neuralink
Brain-Computer Interfaces
Neuralink develops ultra-high-bandwidth brain-machine interfaces with the goal of merging human cognition with AI. Their flagship N1 implant uses thousands of electrodes to record and stimulate neural activity, with the first human trial participant demonstrated cursor control via thought in 2024.
Synchron
Brain-Computer Interfaces
Synchron has developed the Stentrode, a minimally invasive brain-computer interface delivered endovascularly through the jugular vein without open-brain surgery. The device enables paralyzed patients to control digital devices using neural signals and has received FDA Breakthrough Device Designation.
Recently added
Funding spotlight
Abbott Neuromodulation
NYSE: ABT
Acadia Pharmaceuticals
Public · NASDAQ: ACAD
Acer Therapeutics
Public
Advanced Brain Monitoring
Private
Praxis Precision Medicine
Public
Aleva Neurotherapeutics
Series C · $35M
Latest news
Synchron raises $275M Series D to scale its minimally invasive Stentrode BCI toward broad commercial launch in the US and Australia.
MIT's new EEG-based system decodes six discrete emotional states in real time with 94% accuracy, a landmark for non-invasive affective neuroscience.
Synchron's Stentrode Home Edition brings endovascular BCI technology to approved patients outside hospital walls for the first time.
Synchron's implantable brain-computer interface has now been placed in 100 patients globally, setting the stage for a pivotal FDA trial later this year.
Precision Neuroscience raises $160M Series D to expand its minimally invasive brain-computer interface toward broader clinical and commercial deployment.
A 24-month adaptive DBS trial reports significant memory retention improvements in early-stage Alzheimer's patients, reshaping neuromodulation research.
Synchron's Stentrode Home System receives FDA clearance, allowing paralyzed patients to use its implanted BCI independently at home.
The FDA's finalized guidance on adaptive neural devices establishes new evidentiary standards for BCI approvals, reshaping the regulatory landscape.
Every Sunday
The NeuroTech Digest
Funding rounds, breakthroughs, and top jobs — curated weekly for industry professionals.
Subscribe free →For companies
Reach neurotech decision-makers
Premium listings, newsletter sponsorships, and featured placements.
View packages →News & insights
All articles →Synchron Closes $275M Series D to Accelerate Stentrode BCI Commercialization
Synchron raises $275M Series D to scale its minimally invasive Stentrode BCI toward broad commercial launch in the US and Australia.
2026-06-15
MIT Researchers Demonstrate Real-Time Emotion Decoding via Non-Invasive EEG with 94% Accuracy
MIT's new EEG-based system decodes six discrete emotional states in real time with 94% accuracy, a landmark for non-invasive affective neuroscience.
2026-06-13
Synchron Launches Stentrode Home Edition, Expanding BCI Access Beyond Clinical Settings
Synchron's Stentrode Home Edition brings endovascular BCI technology to approved patients outside hospital walls for the first time.
2026-06-11
Synchron Reaches 100-Patient Milestone as Stentrode BCI Moves Toward Pivotal Trial
Synchron's implantable brain-computer interface has now been placed in 100 patients globally, setting the stage for a pivotal FDA trial later this year.
2026-06-09
Precision Neuroscience Closes $160M Series D to Scale Layer 7 Cortical Interface Platform
Precision Neuroscience raises $160M Series D to expand its minimally invasive brain-computer interface toward broader clinical and commercial deployment.
2026-06-06
Closed-Loop Deep Brain Stimulation Demonstrates Sustained Cognitive Benefits in Landmark Alzheimer's Trial
A 24-month adaptive DBS trial reports significant memory retention improvements in early-stage Alzheimer's patients, reshaping neuromodulation research.
2026-06-04
213+
Companies
across 9 sectors
$18B+
VC Invested
tracked in our database
3×/week
News published
Mon · Wed · Fri
8+
Articles
in our archive
Companies by sector
30
Brain-Computer
9
Cognitive
40
Mental
33
Neuromodulation
27
Neuropharmaceuticals
13
Neurodiagnostics
11
Research
10
Neurofeedback
40
Psychedelics
One of the first dedicated neurotech conferences
In 2020, NeuroTech.com hosted one of the world's first digital congresses for neurotechnology — bringing together 20+ world-class researchers, clinicians, and investors across 5 tracks over 12 days.
20+
Speakers
5
Tracks
12
Days
The NeuroTech Digest
Funding rounds, product launches, research breakthroughs, and the best jobs — curated weekly for the neurotech industry.
No spam. Unsubscribe anytime.